34 reports

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Immunotherapy
  • Pathology
  • Germany
  • Product Initiative
  • Anergis SA

Cat allergy is an allergic reaction to one or more allergens produced by cats.

  • Allergy
  • Pathology
  • United States
  • World
  • Product Initiative

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy Immunotherapy
  • Pathology
  • World
  • Product Initiative
  • Anergis SA

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Allergy Immunotherapy
  • Pathology
  • United States
  • Aimmune Therapeutics, Inc.

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Immunotherapy
  • Pathology
  • United States
  • Product Initiative

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Pathology
  • Therapy
  • Biomay AG

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Pathology
  • Therapy
  • Biomay AG

Cat allergy is an allergic reaction to one or more allergens produced by cats.

  • Allergy
  • Chronic Disease
  • Pathology
  • World
  • Product Initiative

HOUSE DUST MITE ALLERGY - PIPELINE BY STALLERGENES GREER PLC, H## 2019 House Dust Mite Allergy - Drug Profiles ALLERGAN FOR DUST MITE ALLERGY - DRUG PROFILE ALLERGEN FOR ALLERGIC ASTHMA AND HOUSE DUST MITE ALLERGY - DRUG PROFILE AM-## -

  • Medical Biotechnology
  • Pathology
  • United States
  • World
  • Product Initiative

" House dust mite allergy is one of the most common allergies, impacting the quality of life for patients across ages and geographies.

  • Pathology
  • Pharmaceutical
  • United States
  • World
  • Product Initiative

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Immunotherapy
  • Pathology
  • United States
  • World
  • Product Initiative

HALMRE-## - DRUG PROFILE POLLINEX QUATTRO GRASS - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Pollinex Quattro Grass Allergy Therapeutics Plc NA GlaxoSmithKline Plc R& D Progress Resea

  • Allergy Drug
  • Ophthalmic Solution
  • Pathology
  • Pharmaceutical
  • Product Initiative

These drugs are useful for treatment of inflammatory diseases, allergy, pain, , asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria etc.

  • Antifungal
  • Pathology
  • Therapy
  • World
  • Sensorion S.A.

THE DRUG CANDIDATE ACTS BY TARGETING DIPEPTIDASE-##.

  • Antifungal
  • Blood Disease
  • Pathology
  • Therapy
  • Bristol-Myers Squibb Company

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Monoclonal Antibody
  • Pathology
  • Respiratory Disease
  • Therapy
  • United States

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Monoclonal Antibody
  • Pathology
  • Targeted Therapy
  • Therapy
  • United States

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Cell Therapy
  • Pathology
  • Therapy
  • Bristol-Myers Squibb Company

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Digestive System Disorder
  • Pathology
  • United States
  • Product Initiative

About ## percent of people who have food allergies are allergic to more than one food.

  • Monoclonal Antibody
  • Pathology
  • Respiratory Disease
  • United States
  • Product Initiative

Rituximab was well tolerated, and most adverse drug reactions were grade ##-## in severity.

  • Monoclonal Antibody
  • Pathology
  • Therapy
  • United States
  • Product Initiative

The molecules developed by Companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ##, ## and ## respectively.

  • Monoclonal Antibody
  • Pathology
  • Therapy
  • United States
  • Product Initiative

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • Pathology
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

In July 2011, Oxagen Limited announced publication of data from a Phase IIa clinical trial of its development drug OC## in the journal Clinical & Experimental Allergy.

  • Asthma
  • Clinical Trial
  • Pathology
  • Respiratory Disease
  • Therapy

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Asthma
  • Pathology
  • Therapy
  • United States
  • Product Initiative

The drug candidate binds to and inhibits the mRNA of Orai ##, inhibiting the calcium transport.

  • Antifungal
  • Ophthalmic Solution
  • Pathology
  • Therapy
  • Aldeyra Therapeutics, Inc.

PI##-KINASE DELTA IS EXPRESSED PRIMARILY IN BLOOD CELL LINEAGES, INCLUDING CELLS THAT CAUSE OR MEDIATE HEMATOLOGIC MALIGNANCIES, INFLAMMATION, AUTOIMMUNE DISEASES AND ALLERGIES.

  • Lymphoma
  • Pathology
  • Therapy
  • United States
  • Product Initiative

PI##-Kinase delta is expressed primarily in blood cell lineages, including cells that cause or mediate hematologic malignancies, inflammation, autoimmune diseases and allergies.

  • Lymphoma
  • Pathology
  • Therapy
  • United States
  • Product Initiative

One patient had a fatal SAE, which was not drug related.

  • Antifungal
  • Lymphoma
  • Pathology
  • Pharmaceutical
  • Therapy

Efficacy was evaluated at Night ## (first drug administration) and after ## weeks of drug administration (Night ##).

  • Pathology
  • Sleep Aid
  • Therapy
  • United States
  • Eisai Co., Ltd.

This explains the need for a high drug dose of IXF-## as supported by the findings of the recently published post-hoc analysis.

  • Monoclonal Antibody
  • Pathology
  • Therapy
  • United States
  • Product Initiative